← Leaderboards
Thomas E Rohan
Yeshiva University
$18,173,673
Attributed
$23,435,234
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,435,234 · 9
By mechanism
R01$22,082,752 · 5
P30$1,352,482 · 4
Top collaborators
- Olivier Loudig6 shared
- John S Condeelis5 shared
Most similar at Yeshiva University
Same institution · by research overlap
- Ruth Macklin$2,225,112
- John S Condeelis$33,385,303
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortMalignant NeoplasmsBaseClinical ResearchCancer RiskGene ExpressionProgramsResearch PersonnelClinical DataPublicationsClinical ManagementEpidemiologyEpidemiology StudyPrognosticCase ControlMolecularNested Case-Control StudyMalignant Breast NeoplasmMemberFormalinParaffin EmbeddingTumorWomanAlbert Einstein Cancer Center
Grant awards (42)
Epidemiology and Clinical Research Informatics Shared Resource$100,996
P30 · FY2025 · CA · contact PI
TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis$635,845
R01 · FY2024 · CA · contact PI
Epidemiology and Clinical Research Informatics Shared Resource$93,316
P30 · FY2024 · CA · contact PI
TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis$866,476
R01 · FY2023 · CA · contact PI
Epidemiology and Clinical Research Informatics Shared Resource$97,816
P30 · FY2023 · CA · contact PI
TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis$858,638
R01 · FY2022 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,134,871
R01 · FY2021 · CA · contact PI
TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis$852,124
R01 · FY2021 · CA · contact PI
Epidemiology & Clinical Research Informatics$107,977
P30 · FY2021 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,225,240
R01 · FY2020 · CA · contact PI
TMEM, MENAcalc, and MENAINV as Prognostic and Predictive Markers for Breast Cancer Metastasis$909,583
R01 · FY2020 · CA · contact PI
Epidemiology & Clinical Research Informatics$107,060
P30 · FY2020 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,178,924
R01 · FY2019 · CA · contact PI
Epidemiology & Clinical Research Informatics$107,060
P30 · FY2019 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,106,638
R01 · FY2018 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$241,213
R01 · FY2018 · CA · contact PI
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ$1,513,571
R01 · FY2017 · CA · contact PI
microRNA expression profiling of benign breast tissue and breast cancer risk$569,377
R01 · FY2014 · CA · contact PI
microRNA expression profiling of benign breast tissue and breast cancer risk$672,589
R01 · FY2013 · CA · contact PI
microRNA expression profiling of benign breast tissue and breast cancer risk$738,155
R01 · FY2012 · CA · contact PI
microRNA expression profiling of benign breast tissue and breast cancer risk$813,924
R01 · FY2011 · CA · contact PI
EPIDEMIOLOGY INFORMATICS SHARED RESOURCE$119,125
P30 · FY2011 · CA · contact PI
CANCER EPIDEMIOLOGY PROGRAM$33,558
P30 · FY2011 · CA · contact PI
microRNA expression profiling of benign breast tissue and breast cancer risk$788,171
R01 · FY2010 · CA · contact PI
EPIDEMIOLOGY INFORMATICS SHARED RESOURCE$114,495
P30 · FY2010 · CA · contact PI
CANCER EPIDEMIOLOGY PROGRAM$33,078
P30 · FY2010 · CA · contact PI
EPIDEMIOLOGY INFORMATICS SHARED RESOURCE$125,981
P30 · FY2009 · CA · contact PI
CANCER EPIDEMIOLOGY PROGRAM$37,334
P30 · FY2009 · CA · contact PI
EPIDEMIOLOGY INFORMATICS SHARED RESOURCE$120,527
P30 · FY2008 · CA · contact PI
CANCER EPIDEMIOLOGY PROGRAM$36,110
P30 · FY2008 · CA · contact PI
EPIDEMIOLOGY INFORMATICS SHARED RESOURCE$90,007
P30 · FY2007 · CA · contact PI
CANCER EPIDEMIOLOGY PROGRAM$28,042
P30 · FY2007 · CA · contact PI
P53 in BBD and Breast Cancer Risk: A Multicenter Cohort$729,783
R01 · FY2006 · CA · contact PI
P53 in BBD and Breast Cancer Risk: A Multicenter Cohort$762,575
R01 · FY2005 · CA
Fat Reduction, HRT Use and Benign Breast Disease Risk$733,164
R01 · FY2005 · CA
P53 in BBD and Breast Cancer Risk: A Multicenter Cohort$759,331
R01 · FY2004 · CA
Fat Reduction, HRT Use and Benign Breast Disease Risk$710,268
R01 · FY2004 · CA
P53 in BBD and Breast Cancer Risk: A Multicenter Cohort$757,685
R01 · FY2003 · CA
Fat Reduction, HRT Use and Benign Breast Disease Risk$707,333
R01 · FY2003 · CA
Fat Reduction, HRT Use and Benign Breast Disease Risk$918,380
R01 · FY2002 · CA
P53 in BBD and Breast Cancer Risk: A Multicenter Cohort$816,422
R01 · FY2002 · CA
Fat Reduction, HRT Use and Benign Breast Disease Risk$1,082,472
R01 · FY2001 · CA